Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Conclusion No differences in efficacy, safety or pharmacokinetic variables were observed between the two treatment arms.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research